Traduction de «results from the california » (Néerlandais → Français) :

Bron : Carcinogenesis, 20-07-12:Joshi AD et al. ; Red meat and poultry, cooking practices, genetic susceptibility and risk of prostate cancer: results from the California Collaborative Prostate Cancer Study.
Source : Carcinogenesis, 20-07-12:Joshi AD et al. ; Red meat and poultry, cooking practices, genetic susceptibility and risk of prostate cancer: results from the California Collaborative Prostate Cancer Study.

Income from associated companies The decline in income from associated companies in the first half of 2009 resulted mainly from reduced contributions from the Roche stake, which included a negative adjustment of USD 40 million since Roche’s reported 2008 results were lower than anticipated.
Résultat provenant des sociétés associées Le repli du résultat provenant des sociétés associées au premier semestre 2009 est dû essentiellement à une réduction des contributions issues de la participation dans Roche, qui incluaient un ajustement à la baisse d’USD 40 millions des résultats de Roche présentés en 2008, lesquels avaient été inférieurs aux attentes.

hypertension alone: 24.8% vs. 13.8%, p < 0.001 Page and 4 [516b] 12,954 singleton Fetal mortality In third trimester: CH Christianso pregnancies in and increase in fetal deaths n, California, USA morbidity and morbidity above 95 1976 from 1959 to mmHg 1967
Middle trimester, stillbirth rate: In white women (n = 10,074): – without proteinuria and < 90mmHg = 8.4 – without proteinuria and º 90 mmHg = 14.8

CORE RESULTS – Reconciliation from IFRS results to core results – Pharmaceuticals (unaudited)
RÉSULTATS CORE – Rapprochement des résultats IFRS des résultats core – Pharmaceuticals (non audités)

CORE RESULTS – Reconciliation from IFRS results to core results – Vaccines and Diagnostics (unaudited)
RÉSULTATS CORE – Rapprochement des résultats IFRS des résultats core – Vaccins et Diagnostic (non audités)

CORE RESULTS – Reconciliation from IFRS results to core results – Sandoz (unaudited)
RÉSULTATS CORE – Rapprochement des résultats IFRS des résultats core – Sandoz (non audités)

CORE RESULTS – Reconciliation from IFRS results to core results – Consumer Health (unaudited)
RÉSULTATS CORE – Rapprochement des résultats IFRS des résultats core – Consumer Health (non audités)

CORE RESULTS Reconciliation from IFRS results to core results – Group – First quarter 2010 (unaudited)
RÉSULTATS CORE Rapprochement des résultats IFRS des résultats core – Premier trimestre 2010 (non audité)

CORE RESULTS – Reconciliation from IFRS results to core results – Alcon, Inc (unaudited)
RÉSULTATS CORE – Rapprochement des résultats IFRS des résultats core – Alcon, Inc (non audités)

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.